Weak Results Stop Pfizer's Tremelimumab Phase III Trial; Bristol Keeps Going

Pfizer discontinues single-agent trial of the CTLA-4 inhibitor in advanced melanoma, but Bristol-Myers Squibb announced it is still moving forward with its CTLA-4 inhibitor ipilimumab, which also failed a monotherapy melanoma trial